{"id":515993,"date":"2020-11-06T18:00:02","date_gmt":"2020-11-06T18:00:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=515993"},"modified":"2020-11-06T18:00:02","modified_gmt":"2020-11-06T18:00:02","slug":"filgrastim-biosimilars-market-value-expected-to-reach-75196-billion-by-2023","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/filgrastim-biosimilars-market-value-expected-to-reach-75196-billion-by-2023_515993.html","title":{"rendered":"Filgrastim Biosimilars Market Value Expected To Reach $751.96 Billion By 2023"},"content":{"rendered":"
\"Filgrastim<\/a><\/p>\n
\n
Filgrastim Biosimilars Global Market Report 2020-30: Covid 19 Growth And Change<\/div>\n<\/div>\n<\/div>\n

Cadila Pharmaceuticals Is One Of The Largest Players In The Filgrastim Biosimilars Market, According To The Business Research Company’s Filgrastim Biosimilars Global Market Report 2020-30: Covid 19 Growth And Change<\/em><\/p>\n

(Companies Covered: Cadila Pharmaceuticals, Dr. Reddy`s Laboratories, Intas Biopharmaceuticals, Sandoz, Amgen Inc., Dr. Reddy`s Laboratories Ltd, Intas Pharmaceuticals, Emcure Pharmaceuticals Ltd., Biocon, Aryogen Biopharma, Claris Life Sciences)<\/em><\/p>\n

The global filgrastim biosimilars market is expected to decline from $511.15 million in 2019 to $445.04 million in 2020 at a compound annual growth rate of -12.93%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $751.96 billion in 2023 at a compound annual growth rate of 19.11%.<\/p>\n

Read More On The Global Filgrastim Biosimilars Market Report At –<\/strong>https:\/\/www.thebusinessresearchcompany.com\/report\/filgrastim-biosimilars-global-market-report-2020-30-covid-19-growth-and-change<\/a><\/p>\n

The filgrastim biosimilars market consists of sales of filgrastim biosimilars and related services by entities (organizations, sole traders and partnerships) that manufacture filgrastim biosimilars. Filgrastim biosimilar treatment is used to stimulate the bone marrow to produce more neutrophils (white blood cells) to fight infection in patients undergoing chemotherapy for cancer treatment. Only goods and services traded between entities or sold to end consumers are included.<\/p>\n

Global Filgrastim Biosimilars Market Segmentation –
<\/strong>1) By Application:<\/strong> Oncology, Chronic and Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases, Others
2) By Distribution Channels:<\/strong> Hospital Pharmacy, Retail Pharmacy, Online Pharmacy.<\/p>\n

Global Filgrastim Biosimilars Market Driver –
<\/strong>Stringent regulations imposed on approvals of biosimilars is anticipated to hinder the growth of the filgrastim biosimilar market in the forecast period. The governments of different regions impose different rules regarding the production and use of biologics and biosimilars.<\/p>\n

Request For A Sample Of The Global Filgrastim Biosimilars Market Report At – <\/strong>https:\/\/www.thebusinessresearchcompany.com\/sample.aspx?id=3426&type=smp<\/a><\/p>\n

Few Points From The Global Filgrastim Biosimilars Market TOC
<\/strong>1. Executive Summary
2. Filgrastim Biosimilars Market Characteristics
3. Filgrastim Biosimilars Market Size And Growth
3.1. Global Filgrastim Biosimilars Historic Market, 2015 – 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Filgrastim Biosimilars Forecast Market, 2019 – 2023F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market
4. Filgrastim Biosimilars Market Segmentation
4.1. Global Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
4.2. Global Filgrastim Biosimilars Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5. Filgrastim Biosimilars Market Regional And Country Analysis
5.1. Global Filgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global Filgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion<\/p>\n

Interested to know more about The Business Research Company?
<\/strong>The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> The Business Research Company<\/a>
Contact Person:<\/strong> Oliver Guirdham
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +44 20 7193 0708
Address:<\/strong>
City:<\/strong> London
State:<\/strong> Greater London
Country:<\/strong> United Kingdom
Website:<\/strong> https:\/\/www.thebusinessresearchcompany.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Filgrastim Biosimilars Global Market Report 2020-30: Covid 19 Growth And Change Cadila Pharmaceuticals Is One Of The Largest Players In The Filgrastim Biosimilars Market, According To The Business Research Company’s Filgrastim Biosimilars Global Market Report 2020-30: Covid 19 Growth And … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,416],"tags":[],"class_list":["post-515993","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/515993","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=515993"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/515993\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=515993"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=515993"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=515993"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}